Biotech News
Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Achieved YUTREPIA ® net product sales of $148.3 million for the full year 2025 with $90.1 million in the fourth quarter More than 3,600 unique prescriptions received and 2,900 patients treated to date since launch in June 2025 Ended 2025 with $190.7 million in cash and cash equivalents, an increase